99 related articles for article (PubMed ID: 6104700)
21. The neurochemistry of Parkinson's disease: effect of L-dopa therapy.
Lloyd KG; Davidson L; Hornykiewicz O
J Pharmacol Exp Ther; 1975 Dec; 195(3):453-64. PubMed ID: 489
[TBL] [Abstract][Full Text] [Related]
22. Biochemical alterations of dopamine receptor responses following chronic L-dopa therapy.
Wilner KD; Butler IJ; Seifert WE; Clement-Cormier YC
Biochem Pharmacol; 1980 Mar; 29(5):701-6. PubMed ID: 20227943
[TBL] [Abstract][Full Text] [Related]
23. Assessment of dopamine and its metabolites in the intracellular and extracellular compartments of the rat striatum after peripheral administration of L-[11C]dopa.
Miwa S; Gillberg PG; Bjurling P; Yumoto N; Odano I; Watanabe Y; Långström B
Brain Res; 1992 Apr; 578(1-2):122-8. PubMed ID: 1511268
[TBL] [Abstract][Full Text] [Related]
24. Effect of the adenosine A2A receptor antagonist 8-(3-chlorostyryl)caffeine on L-DOPA biotransformation in rat striatum.
Gołembiowska K; Dziubina A
Brain Res; 2004 Feb; 998(2):208-17. PubMed ID: 14751592
[TBL] [Abstract][Full Text] [Related]
25. Dopaminergic metabolism in various rat brain areas after L-dopa loading.
el Gemayel G; Trouvin JH; Prioux-Guyonneau M; Jacquot C; Cohen Y
J Pharm Pharmacol; 1986 Sep; 38(9):691-4. PubMed ID: 2877071
[TBL] [Abstract][Full Text] [Related]
26. 3-O-methyldopa blocks dopa metabolism in rat corpus striatum.
Reches A; Fahn S
Ann Neurol; 1982 Sep; 12(3):267-71. PubMed ID: 7137962
[TBL] [Abstract][Full Text] [Related]
27. Subacute L-DOPA in mice: biochemical and behavioural effects.
Jenkins O; Bailey R; Crisp E; Jackson DM
Psychopharmacology (Berl); 1980; 68(1):77-83. PubMed ID: 6771801
[TBL] [Abstract][Full Text] [Related]
28. β-asarone and levodopa co-administration increase striatal dopamine level in 6-hydroxydopamine induced rats by modulating P-glycoprotein and tight junction proteins at the blood-brain barrier and promoting levodopa into the brain.
Huang L; Deng M; He Y; Lu S; Ma R; Fang Y
Clin Exp Pharmacol Physiol; 2016 Jun; 43(6):634-43. PubMed ID: 26991136
[TBL] [Abstract][Full Text] [Related]
29. Aromatic L-amino acid decarboxylase immunoreactive cells in the rat striatum: a possible site for the conversion of exogenous L-DOPA to dopamine.
Mura A; Jackson D; Manley MS; Young SJ; Groves PM
Brain Res; 1995 Dec; 704(1):51-60. PubMed ID: 8750961
[TBL] [Abstract][Full Text] [Related]
30. Manganese increases L-DOPA auto-oxidation in the striatum of the freely moving rat: potential implications to L-DOPA long-term therapy of Parkinson's disease.
Serra PA; Esposito G; Enrico P; Mura MA; Migheli R; Delogu MR; Miele M; Desole MS; Grella G; Miele E
Br J Pharmacol; 2000 Jun; 130(4):937-45. PubMed ID: 10864903
[TBL] [Abstract][Full Text] [Related]
31. [Interactions of cerebral serotonin and catecholamines].
Watanabe Y
Nihon Yakurigaku Zasshi; 1983 May; 81(5):365-83. PubMed ID: 6195056
[TBL] [Abstract][Full Text] [Related]
32. Extracellular concentrations of dopamine and metabolites in the rat caudate after oral administration of a novel catechol-O-methyltransferase inhibitor Ro 40-7592.
Acquas E; Carboni E; de Ree RH; Da Prada M; Di Chiara G
J Neurochem; 1992 Jul; 59(1):326-30. PubMed ID: 1613509
[TBL] [Abstract][Full Text] [Related]
33. Levodopa and 3-OMD levels in Parkinson patients treated with Duodopa.
Antonini A; Bondiolotti G; Natuzzi F; Bareggi SR
Eur Neuropsychopharmacol; 2010 Oct; 20(10):683-7. PubMed ID: 20570113
[TBL] [Abstract][Full Text] [Related]
34. Pergolide potentiates L-DOPA-induced dopamine release in rat striatum after lesioning with 6-hydroxydopamine.
Dethy S; Laute MA; Damhaut P; Goldman S
J Neural Transm (Vienna); 1999; 106(2):145-58. PubMed ID: 10226935
[TBL] [Abstract][Full Text] [Related]
35. Locomotor response to L-DOPA in reserpine-treated rats following central inhibition of aromatic L-amino acid decarboxylase: further evidence for non-dopaminergic actions of L-DOPA and its metabolites.
Alachkar A; Brotchie JM; Jones OT
Neurosci Res; 2010 Sep; 68(1):44-50. PubMed ID: 20542064
[TBL] [Abstract][Full Text] [Related]
36. β-asarone and levodopa coadministration increases striatal levels of dopamine and levodopa and improves behavioral competence in Parkinson's rat by enhancing dopa decarboxylase activity.
Huang L; Deng M; Zhang S; Lu S; Gui X; Fang Y
Biomed Pharmacother; 2017 Oct; 94():666-678. PubMed ID: 28787702
[TBL] [Abstract][Full Text] [Related]
37. Chronic L-dopa treatment in the unilateral 6-OHDA rat: evidence for behavioral sensitization and biochemical tolerance.
Carey RJ
Brain Res; 1991 Dec; 568(1-2):205-14. PubMed ID: 1814568
[TBL] [Abstract][Full Text] [Related]
38. Intrastriatal inhibition of aromatic amino acid decarboxylase prevents l-DOPA-induced dyskinesia: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine lesioned rats.
Buck K; Ferger B
Neurobiol Dis; 2008 Feb; 29(2):210-20. PubMed ID: 17920284
[TBL] [Abstract][Full Text] [Related]
39. Binding of dopamine and 3-methoxytyramine as l-DOPA metabolites to human alpha(2)-adrenergic and dopaminergic receptors.
Alachkar A; Brotchie JM; Jones OT
Neurosci Res; 2010 Jul; 67(3):245-9. PubMed ID: 20302892
[TBL] [Abstract][Full Text] [Related]
40. Assessment of renal dopaminergic system activity during cyclosporine A administration in the rat.
Pestana M; Vieira-Coelho MA; Pinto-do-O PC; Fernandes MH; Soares-da-Silva P
Br J Pharmacol; 1995 Aug; 115(8):1349-58. PubMed ID: 8564191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
